z-logo
Premium
Plasma HMGB ‐1 after the initial dose of epirubicin/docetaxel in cancer
Author(s) -
Arnold Tobias,
Michlmayr Anna,
Baumann Suzann,
Burghuber Christopher,
Pluschnig Ursula,
Bartsch Rupert,
Steger Guenther,
Gnant Michael,
Bergmann Michael,
BachleitnerHofmann Thomas,
Oehler Rudolf
Publication year - 2013
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12043
Subject(s) - epirubicin , docetaxel , medicine , breast cancer , oncology , chemotherapy , pathological , cancer
Background The response of breast cancer patients to neoadjuvant chemotherapy ( NCT ) is highly heterogeneous, and reliable predictive instruments remain to be defined. High‐mobility group box‐1 ( HMGB ‐1) protein is a cell death marker, which is easily detectable in plasma. We hypothesized that the initial dose of NCT with epirubicin/docetaxel induces changes in plasma HMGB ‐1 which could allow for an early prediction of response to therapy. Materials and methods First, we analysed whether epirubicin/docetaxel releases HMGB ‐1 from HCC 1143 breast cancer cells in vitro . Thereafter, plasma HMGB ‐1 levels before and 1–4 days after the first dose of epirubicin/docetaxel‐based NCT were determined in 41 breast cancer patients and correlated with pathological response to treatment. Results Treatment of HCC 1143 cells with epirubicin/docetaxel resulted in a significant HMGB ‐1 release in vitro . In vivo , HMGB ‐1 levels increased significantly only in responders (pathological complete response or partial remission, n  = 22) but not in nonresponders (stable or progressive disease, n  = 19). Conclusion Our data suggest that early dynamic changes of plasma HMGB 1 could be a promising biomarker to predict the final response to NCT in breast cancer patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here